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 Abstract 
Purpose 
To predict the tramadol in vivo pharmacokinetics in adults by using in vitro metabolism data and an 
in vitro-in vivo extrapolation (IVIVE)-linked physiologically-based pharmacokinetic (PBPK) modeling 
and simulation approach (Simcyp®). 
Methods 
Tramadol metabolism data was gathered using metabolite formation in human liver microsomes 
(HLM) and recombinant enzyme systems (rCYP). Hepatic intrinsic clearance (CLintH) was (i) estimated 
from HLM corrected for specific CYP450 contributions from a chemical inhibition assay (model 1); (ii) 
obtained in rCYP and corrected for specific CYP450 contributions by study-specific intersystem 
extrapolation factor (ISEF) values (model 2); and (iii) scaled back from in vivo observed clearance 
values (model 3). The model-predicted clearances of these 3 models were evaluated against 
observed clearance values in terms of relative difference of their geometric means, the fold 
difference of their coefficients of variation, and relative CYP2D6 contribution. 
Results 
Model 1 underpredicted, while model 2 overpredicted the total tramadol clearance by -27% and 
+22%, respectively. The CYP2D6 contribution was underestimated in both models 1 and 2. Also, the 
variability on the clearance of those models was slightly underpredicted. Additionally, blood-to-
plasma ratio and hepatic uptake factor were identified as most influential factors in the prediction of 
the hepatic clearance using a sensitivity analysis. 
Conclusion 
IVIVE-PBPK proved to be a useful tool in combining tramadol’s low turnover in vitro metabolism data 
with system-specific physiological information to come up with reliable PK predictions in adults. 
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1 Abbreviations 
PBPK: physiologically-based pharmacokinetics 
IVIVE: in vitro-in vivo extrapolation 
CLint: intrinsic clearance 
HLM: human liver microsomes 
rCYP: recombinant CYP450 enzyme systems 
ISEF: inter-system extrapolation factor 
ODT: O-desmethyltramadol 
NDT: N-desmethyltramadol 
NODT: N,O-didesmethyltramadol 
 2 Introduction 
Tramadol is a centrally acting analgesic drug with weak opioid activity and has an established use in 
the clinical setting (1). Tramadol is metabolized by different cytochrome P450 enzymes (CYP450), of 
which CYP3A4 and CYP2D6 are deemed to be the most important ones (2, 3) (figure 1). CYP3A4 
governs the metabolism of about 50% of clinically used drugs and is characterized by large 
interindividual variability (4). Also for CYP2D6 genetic polymorphisms have been described that can 
lead to large interindividual variation in substrate  pharmacokinetics (5). Tramadol, which inhibits 
neuronal uptake of norepinephrine and serotonine, is bio-activated by CYP2D6 to its O-demethylated 
metabolite that has 300 times more affinity for the -opioid receptor than tramadol (1). Therefore, 
CYP2D6 activity and metabolizer status may have implications on the pharmacokinetics and on the 
extent of -opioid effect after administration of this drug (6, 7). The above described metabolism 
properties make this drug an interesting compound to study the performance of bottom-up 
physiologically-based pharmacokinetic (PBPK) modeling, relying on in vitro drug metabolism kinetics 
to predict in vivo pharmacokinetics. 
Figure 1 here 
In the past, the use of PBPK models was limited due to their complexity and high computational 
requirements. Therefore, simpler, empirical methods such as sums of exponentials and 
compartmental models, were commonly chosen to ‘describe’ the (plasma) concentration-time 
profiles (8). PBPK models represent the studied organism as a closed circulatory system in which 
organs and different tissues make up the physiologically relevant compartments, interconnected by 
the blood circulation, independent of the drug under investigation (9). In order to make compound-
specific PBPK predictions, compound-specific information, such as molecular descriptors logP, pKa, 
molecular weight (Mw), and in vitro measured values intrinsic clearance (CLint), Km, Vmax, blood-
plasma ratio, fraction unbound in plasma have to be provided (10). The mechanistic extrapolation of 
in vitro pharmacokinetic data to in vivo is the so-called bottom-up IVIVE-linked PBPK approach and 
allows to predict first-in-man pharmacokinetic exposure, anticipate major drug-drug interactions, 
and predict drug clearance in subject populations at risk (e.g. renal/hepatic impaired, pediatric 
populations) (11, 12). Furthermore, this bottom-up PBPK approach is able to a priori identify 
disposition covariates of a new drug candidate through in vitro investigation, and can provide 
mechanistic insight in the observed absorption, distribution, metabolism, and excretion properties of 
the studied compound. Nevertheless, the classical ‘top-down’ approach will remain a vital 
complementary tool to adequately describe the observed data obtained in clinical studies (13). 
In IVIVE, it is extremely important that the metabolic enzyme kinetic data are obtained under optimal 
conditions to build a robust quantitative PBPK model. Intrinsic metabolic drug clearance values can 
be determined by using metabolite formation or substrate depletion assays. In substrate depletion 
assays, the in vitro half-life of the drug is determined (14) and at least 20% compound turnover is 
required for analytical reasons. In such assays, especially for low clearance drugs, long incubation 
times and relatively high protein concentrations are needed. This may lead to issues such as loss in 
enzyme activity over time, end product inhibition, and binding problems, thus preventing reliable 
prediction of drug clearance. However, other methods (such as the hepatocyte relay method) are 
now available that allow accurate and precise measurement of compounds with low in vitro turnover 
(15). Metabolite formation assays use initial rates, enabling the use of shorter incubation times and 
lower protein concentrations. However, reference standards for metabolites are needed for the 
bioanalysis. Underprediction of clearance can occur if not all metabolic pathways are accounted for 
(16). As an alternative, formation of all metabolites originating from a parent compound can be 
studied by using a radiolabel in the incubation experiments. 
In this manuscript we present an extended case study on the IVIVE-PBPK prediction of tramadol. The 
hepatic intrinsic clearance (CLintH) was estimated using 3 different clearance models: CLintH from 
human liver microsomal (HLM) metabolism data corrected for specific CYP450 contributions from a 
chemical inhibition assay (model 1, HLM model); CLintH obtained from recombinant enzyme systems 
corrected for specific CYP450 contributions by study-specific intersystem extrapolation factor (ISEF) 
values (model 2, rCYP model); and CLintH scaled back from in vivo observed clearance values (model 
3, retrograde model). Besides, we highlight a number of essential aspects regarding the design of the 
in vitro enzyme kinetic experiments and discuss the role of PBPK in the bottom-up scaling of these 
data to in vivo PK.
 3 Materials and Methods 
3.1 Chemicals and Materials 
All chemicals and reagents used were of the highest available grade: Na2HPO4, KH2PO4, KCl, MgCl2, 
NADP, HCL (Merck, Darmstadt, Germany), glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase (Roche Diagnostics GmbH, Manheim, Germany), Tramadol (TRC inc, Toronto, 
Canada), O-desmethyltramadol (ODT) (TRC inc, Toronto, Canada), N-desmethyltramadol (NDT) (LGC 
GmbH, Luckenwalde, Germany), N,O-didesmethyltramadol (NODT) (TRC inc, Toronto, Canada), O-
desmethyltramadol-D6 (TRC inc, Toronto, Canada), 14C-tramadol (Isotope Synthesis, Janssen). 
 
3.2 Incubations with Human Liver Microsomes 
A human liver microsomal pool (BD Biosciences, Woburn, USA), used for tramadol enzyme kinetics 
investigation, consisted of 50 adult donors and was stored at -80°C in an Ultra Freezer (New 
Brunswick scientific, Rotselaar, Belgium). Incubation mixtures (total volume 600 µl) consisted of 297 
µl microsomal protein, 3 µl of a tramadol solution, and 300 µl cofactor mix containing an NADPH-
regenerating system consisting of 1 mg of glucose-6-phosphate, 0.50 units of glucose-6-phosphate 
dehydrogenase, 0.25 mg of NADP and 1 mg of MgCl2.6H2O in 1 ml of 0.5 M Na,K-phosphate buffer pH 
7.4. Final microsomal protein concentrations ranged from 0.5 to 2 mg protein/ml. A preincubation 
with cofactor mix was done for 5 minutes in a shaking water bath at 37°C (100 oscillations/min) 
(Thermo, Waltham, USA). Incubations were started by adding 3 µl of a tramadol solution, resulting in 
a final concentration of 0.5, 1, 5, 20, 50, 100, 150, and 200 µM. Reactions were stopped at 2, 5, 7, 10, 
20, and 30 min by transferring 100 µl aliquots  into 96-well plates containing 10 µl ice-cold 4N HCl 
and 10 µl of internal standard (O-desmethyltramadol-D6, 6 ng/ml). For each substrate and protein 
concentration level, samples were incubated in duplicate or triplicate and boiled control incubates 
were run in parallel to correct for non-enzymatic degradation. 96-well plates were then stored at -
20°C waiting to be analyzed by UPLC-MS/MS. 
 
3.3 Inhibition assays with Human Liver Microsomes 
Incubation mixtures were essentially the same as described above but relative volumes differed due 
to the addition of inhibitors, and contained 294 µl of microsomal protein, 300 µl of cofactor mix, 3 µl 
of inhibitor, and 3 µl of a tramadol solution. The final concentration of microsomal protein and 
tramadol in the incubations was 0.5 mg/ml and 1 µM, respectively. Inhibitors, which were dissolved 
in methanol in order to minimize solvent effects (0.5%), were ketoconazole (CYP3A inhibitor, 1 µM), 
SR-9186 (CYP3A4 inhibitor, 2.5 µM), quinidine (CYP2D6 inhibitor, 1 µM), and thioTEPA (CYP2B6 
inhibitor, 10 µM). Incubations with the mechanism-based inhibitors SR-9186 and thioTEPA were 
equilibrated in a shaking water bath at 37°C (100 oscillations/min) (Thermo, Waltham, USA) for 5 and 
15 min, respectively, and were then started by the addition of tramadol. A 5 min equilibration time 
was used for the reversible inhibitors ketoconazole and quinidine. All samples were stopped at 10 
min in 96-well plates, containing 10 µl ice-cold 4N HCl and 10 µl of internal standard. Linearity 
controls (incubation mixtures without inhibitors; tramadol 1 µM, 0.5 mg protein/ml, 10 min) as well 
as boiled controls were run in parallel to allow determination of the inhibited fraction and to correct 
for background, respectively. 96-well plates were then stored at -20°C waiting to be analyzed by 
UPLC-MS/MS. 
 
3.4 Incubations with recombinant CYP450 enzymes 
Supersomes™ are membrane fractions derived from baculovirus infected insect cells expressing a 
specific (selection of) drug metabolizing enzyme(s), i.e. CYP450 enzymes with or without NADPH 
cytochrome P450 reductase and cytochrome b5. Supersomes™ (BD Biosciences, Woburn, USA) were 
used in order to investigate the enzyme kinetic behavior of tramadol for the isolated CYPs. 
Incubation mixtures contained 297 µl of a given recombinant isoform at a final 100 pmol/ml (CYP 
isoform) concentration, together with 300 µl of the cofactor mix containing an NADPH-regenerating 
system (composition cfr Materials and Methods 2nd paragraph). These mixtures were preincubated in 
a shaking water bath at 37°C (100 oscillations/min) (Thermo, Waltham, USA) for 5 min and 
incubations were started by adding 3 µl of a tramadol solution. Tramadol final test concentrations 
were 1, 5, 150, and 250 µM. Reactions were stopped at 2, 5, 7, and 10 min by transferring 100 µl 
aliquots into 96-well plates containing 10 µl ice-cold 4N HCl and 10 µl of internal standard. For each 
substrate and each recombinant isoform, samples were incubated in duplicate and SupersomeTM 
insect controls, consisting of membrane fractions containing all proteins from the insect cell line 
except the CYP450 component, were run in parallel to correct for background. 96-well plates were 
then stored at -20°C waiting to be analyzed by UPLC-MS/MS. 
 
3.5 Bioanalysis 
Tramadol’s main metabolites O-desmethyl tramadol (ODT, M1),N-desmethyl tramadol (NDT, M2), 
and N,O-didesmethyl tramadol (NODT, M5) (1) were quantified by a sensitive UPLC-MS/MS method. 
The Nexera UHPLC system (Shimadzu, Kyoto, Japan), consisting of a RackChanger II, SIL-30AC 
autosampler, CTO-30A column oven, and LC30AD pump units was linked via a Valco switching valve 
to an API 4000 QTRAP (AB Sciex, Toronto, Canada) equipped with a Turbo VTM ion source in ESI+ 
mode. For the chromatographic separation, a gradient was run -with solvents A (0.025M ammonium 
acetate, pH 8.5) and B (acetonitrile:methanol 80:20, v/v)- from 5% to 50% B in 3 min, to 100% B in an 
immediate step gradient, held for 0.3 min, and back to 5% B, allowing 2 min re-equilibration, at a 
flow rate of 0.6 ml/min. The column was an Acquity UPLC BEH C18 1.7µm 50x2.1mm column 
(Waters, Milford, USA) packed with 1.7 µm particles and maintained at 60°C. 
Metabolite formation was quantified by use of a calibrator set and quality control samples that were 
prepared by spiking 25 µl of reference standard solutions N-desmethyl tramadol (NDT), O-desmethyl 
tramadol (ODT), N,O-didesmethyl tramadol (NODT) containing O-desmethyltramadol-D6 as internal 
standard (6 ng/ml) to a mixture of 250 µl microsomal matrix and stopped with 25 µl 4N HCl. 
Depending on the expected extent of metabolite formation 10 calibrator levels (ranging 200-fold) 
and 3 QC levels (low, medium, high; made in duplicate) were selected for each analytical batch. Runs 
were accepted based on recommendations from the FDA’s “Guidance for Industry– Bioanalytical 
Method Validation”. At least 4 out of 6 QC samples were within 15% of their nominal value, for the 
calibration curve simple linear regression was applied with a weighting factor 1/x. Standards deviated 
not more than 15% from the nominal concentration, except for the LLOQ where 20% deviation was 
allowed. Samples in 96-well plates were thawed while shaking, submersed in an ultrasone bath, and 
centrifuged using an AllegraTM 25R ultracentrifuge (Beckman Coulter, Suarlée, Belgium). Depending 
on the expected degree of metabolite formation, between 1 and 10 µl supernatant was directly 
injected onto the column to assess concentrations of ODT, NDT, and NODT in the incubation 
samples. 
 
3.6 Tramadol enzyme kinetics and IVIVE 
Concentrations of metabolites in the incubation samples were corrected for protein concentration 
(mg microsomal protein/ml), reaction time (min), and initial substrate concentration (µM) in order to 
calculate the apparent in vitro clearance (CLapp) for every metabolite. CLapp was plotted vs. tramadol 
incubation concentration and a nonlinear model –with the model structure provided in equation 1-  
was fitted to the data, using the R statistics program (17). Models were evaluated by visually 
inspecting residual plots for bias. In  equation 1 CLapp is the apparent in vitro clearance, expressed as 
µl/min/mg microsomal protein, vo is the initial rate of metabolite formation in the incubate 
(pmol/min/mg protein), [S] is tramadol concentration (µM), Km and Vmax are the Michaelis-Menten 
constant (µM) and maximum velocity (pmol/min/mg protein), respectively. This equation allowed 
estimation of the parameters Km and Vmax, and hence the calculation of CLint. 
 
Equation 1 
 
When the substrate concentration in the incubate is substantially below the Km (in practice [S]< 
Km/10), the intrinsic clearance (CLint) can be approximated from the ratio of Vmax/Km. When the 
substrate concentration is at Km, the CLapp approximates the half maximal CLint. 
Tramadol incubation concentrations (0.5 to 250 µM) were chosen to be near the therapeutic plasma 
concentrations observed in vivo (Cmax 2.25 µM (1)) in order to define the enzyme kinetic parameters 
of tramadol at a therapeutically relevant concentration test range. An unbound fraction in 
microsomes (fumic) of  ~0.96 was estimated in silico using the prediction toolbox in Simcyp® V12.1 
(18). 
By scaling up an in vitro obtained (unbound) intrinsic clearance (CLintu) with mechanistic information 
on the liver abundance of each CYP, the amount of microsomal protein per gram liver (MPPGL), and 
liver weight, a determination of the in vivo hepatic intrinsic clearance (CLintH) can be obtained. 
Additionally, known variability in demographic and biological components is incorporated in order to 
predict drug disposition in relevant individuals with realistic variability. Additionally, for the scaling 
from recombinant systems, an intersystem extrapolation factor (ISEF) corrects for the inherent 
activity difference between recombinant systems and HLM (19, 20).  
Equations 2 and 3 are used for the mechanistic scaling of unbound intrinsic clearance to hepatic 
intrinsic clearance , obtained from HLM and recombinant systems, respectively. For scaling up HLM 
unbound CLint, the amount of microsomal protein per gram liver (MPPGL), and liver weight are 
needed to provide an estimate of the in vivo hepatic intrinsic clearance (CLintH) (equation 2). For 
scaling up the unbound CLint determined from rCYP systems, the CYP450 isoform abundance in vivo 
and the ISEF value are additional factors needed to calculate the hepatic CLint (equation 3) (19).  
 
Equation 2 
 
 
Equation 3 
 
Subsequently, the hepatic intrinsic clearance (CLintH) is integrated with the fraction unbound in 
plasma (fup), blood-to-plasma ratio (BP) and the hepatic blood flow (QH) in the commonly used well-
stirred liver model in order to obtain an estimate of the hepatic plasma clearance (CLH), as illustrated 
in equation 4: 
 
Equation 4 
 
3.7 Blood distribution 
The blood distribution of tramadol was investigated by incubating a tramadol concentration range 
(0.1 – 10 µM) in whole blood. Fresh whole blood was collected from 3 healthy male volunteers in 
EDTA-coated tubes to which 14C-tramadol was spiked (no organic solvents were used). Spiked whole 
blood was left to equilibrate for 30 min in a shaking water bath Grant (type OLS200) (Grant 
instruments, Cambridge, UK) at 37°C and was gently homogenized every 10 min. After 30 min, 3 
homogenous aliquots of 100 µl were pipetted to oxidation cups and the rest of the whole blood 
sample was centrifuged for 10 min at 1700g in a Hettich Rotixa (type 50S) (Hettich AG, Tuttlingen, 
Germany). 2 aliquots of 100 µl plasma were placed in counting vials together with scintillation fluid 
Ultima Gold (PerkinElmer, Waltham, USA) and were counted by liquid scintillation counting (LSC) in a 
Tri-carb® 2900 TR  (PerkinElmer, Waltham, USA). Whole blood samples were combusted in a Packard 
Sample Oxidizer 307 (PerkinElmer, Waltham, USA), released 14CO2 was trapped with Carbosorb and 
mixed with scintillation fluid, and submitted to LSC. The radioactivity was measured in an aliquot of 
whole blood as well as in plasma from the same sample in order to assess the ratio of the whole 
blood concentration vs. the plasma concentration (blood-to-plasma or B:P ratio). 
 
3.8 Simulations 
An intravenous full PBPK model was selected in the Simcyp® Simulator V12.1 (Sheffield, UK) to 
predict pharmacokinetics as a function of time. In order to verify the simulations, PK parameters 
were compared to in vivo data (21-24). 
The virtual clinical trial design was set to capture the pharmacokinetics as a function of time for a 100 
mg tramadol iv bolus up to 24h post-dose, in line with the in vivo observed AUC’s which were also 
obtained from 0 to 24h. Following molecular descriptors were extracted from literature and used as 
input for the PBPK model: molecular weight 264.4; logP 1.35; pKa 9.41; BP ratio 1.09 (own 
experiments); fup 0.8. 
The virtual population was set to mimic the reference population in terms of the proportion male-
female (30% female), the age range (23-57 years), and CYP2D6 metabolizer status (8.2% PM – 86.5% 
EM – 5.3% UM). 
The distribution component of the PBPK model was represented by the Rodgers & Rowland model 
(method 2 in Simcyp®). The Rodgers and Rowland equation was used since this equation, in contrast 
to the Poulin and Theil equation (method 1 in Simcyp®), takes into account a tissue’s acidic 
phospholipid fraction and takes explicit account of the extent of ionization of a compound at the pH 
of the compartment concerned. Since tramadol is almost completely ionized at pH 7.4, the Rodgers 
and Rowland equation will assume that binding to acidic phospholipids controls the distribution 
within the body (25). The elimination component of the PBPK model involved a renal and a hepatic 
clearance part. The renal plasma clearance was mechanistically predicted at 6.6 L/h (110 ml/min) 
using the permeability-limited mechanistic kidney model. Since this value was in good agreement 
with in vivo observations the renal clearance was fixed at 6.6 L/h for further simulations. The hepatic 
plasma clearance was investigated by means of an IVIVE-linked elimination model using kinetic data 
from in vitro experiments, further elaborated hereunder in the section “Hepatic clearance 
investigation”. In addition, a sensitivity analysis was conducted to assess model robustness to 
changing input parameters other than CLint values, as well as a population simulation comparing the 
geometric means of clearance and volume of distribution and their associated variabilities with the 
reference data set used in this study (21-24). 
3.8.1 Hepatic clearance investigation 
The CYP-isoform specific CLint values that were used in the 3 different clearance modeling 
approaches, described hereunder, can be found in table 1. A factor of 1.58 was used to account for 
hepatic accumulation of the basic amine tramadol (see discussion for details). 
 
The HLM model (model 1) represents input from intrinsic clearance values obtained in HLM for the 
two main tramadol CYP-mediated metabolites ODT and NDT (table 2). The contribution of different 
CYP450 enzymes to the total intrinsic clearance per metabolite is estimated based on the effect of 
different chemical inhibitors (table 1). The rCYP model (model 2) consists of intrinsic clearance values 
obtained in isolated recombinant enzyme systems CYP3A4, 2D6, and 2B6 for the two main tramadol 
CYP450-mediated metabolites ODT and NDT (table 1). ISEF values for CYP3A4 and CYP2D6 were 
determined for scaling up tramadol rCYP450 kinetic data using probe substrates midazolam and 
dextromethorphan, respectively. CLint values for both probes were obtained in HLM as well as in 
rCYP systems, and specific CYP abundances of 137 and 8 pmol/mg microsomal protein were used to 
calculate the ISEF values for CYP3A4 and CYP2D6 (table 1), respectively (26, 27). For CYP2B6, an ISEF-
value of 0.43 was used as provided by Simcyp V12.1. The retrograde model (model 3) calculates a 
retrograde hepatic intrinsic clearance per CYP isoform based on apparent in vivo CYP contributions in 
the total metabolism (table 1). Therefore, it can serve as a reference model next to the 2 other 
models in evaluating the prediction of the population clearance. Simulations were performed using a 
study design and healthy volunteer population that resembled the study design and covariate 
characteristics of the reference study, respectively (21-24). The simulations were executed using 
virtual populations of 1000 subjects 
The CYP2D6 contribution in the current clearance models was assessed by comparing the fold 
increase in hepatic clearance between PM and EM with observed data from a study conducted by 
Pedersen et al. (28). Patients from this study were genotyped as *1/*1 (EM; n=8) and *4/*4 (n=7) or 
*4/*6 (PM) (n=1). The PBPK trial design was set to resemble the actual trial design as closely as 
possible by taking into account the actual age range, administered dose, proportion of male-female, 
and metabolizer phenotype in the 2 groups. One thousand virtual patients were simulated for every 
run. 
 
3.8.2 Population simulation 
In Simcyp®, known covariates or correlations of different specifications of the population as well as 
the observed variability associated with each parameter involved in the bottom-up approach is 
considered to generate virtual subjects representative of those in the real world (10). Therefore, a 
population simulation was set up to investigate how well the 3 IVIVE-linked PBPK models could 
predict the population values of the clearance (CL) and volume of distribution (Vss) as well as their 
associated variability. In that respect the relative difference of the predicted and observed geometric 
means, calculated as (predicted-observed)/observed*100%, was used to compare the population 
values of CL and Vss. To compare the predicted and observed variability in the population, the fold 
difference of the predicted and observed coefficients of variation (CV) was used, assuming that these 
PK parameters follow log-normal distributions (table 3). Evaluation was based on visual inspection of 
observed and predicted 95% prediction intervals, calculated as suggested by Johnson et al (29). The 
simulated virtual population consisted of 1000 patients that mimicked the dosage, age range and 
male-female proportion of the reference studies (21-24).  
 
3.8.3 Sensitivity Analysis 
A sensitivity analysis was undertaken in order to define to what extent other input parameters than 
intrinsic clearance would influence the prediction of clearance (CL) using the clearance model 1 
(based on HLM values) and volume of distribution (Vss) using the distribution model based on the 
Rodgers equations (25). Five input parameters of interest (logP, pKa, fraction unbound in plasma (fu), 
B:P ratio (BP), drug accumulation in hepatocyte (ACC)) were varied within the PBPK model (full 
factorial design (25)), using the Simcyp® Batch processor, between the lowest and the highest value 
published in literature or own experimental results. Following values (low level – high level) were 
used as input to the PBPK model: logP (1.35- 2.41), pKa (9.14 – 9.44), fu (0.74 – 0.80), BP (1.09 – 
1.20), ACC (1.5 – 3). The reason for varying the ACC factor 2-fold can be found in the discussion. PBPK 
simulations were performed using a healthy volunteer population that resembled the study 
population of the reference studies  (21-24). One hundred virtual patients were simulated for every 
run. The prediction results were interpreted by means of a generalized linear model (glm) that was 
fitted to the PBPK prediction results, so as to disentangle the effects of the input parameters and 
their interactions on the prediction of CL and Vss.  
 4 Results 
4.1 In vitro results 
4.1.1 CLint from HLM assays 
The metabolism kinetics of 0.5 µM to 250 µM tramadol to its two primary metabolites O-desmethyl 
tramadol (ODT) and N-desmethyl tramadol (NDT) was determined in pooled human liver 
microsomes. The secondary metabolite N,O-didesmethyl tramadol (NODT) was always about 1% and 
< 3% of the amount of NDT and ODT formed, respectively, implying negligible underestimation of 
enzyme kinetic parameters due to secondary metabolism. Furthermore, preliminary experiments 
using 14C-tramadol (data not shown) it was demonstrated that no other metabolites were formed 
than the ones described in this paper. The aim was to identify the intrinsic clearance for both 
metabolites at concentrations well below Km values, previously reported by Subrahmanyam et al. (2) 
(KmODT 116 µM; KmNDT 1021 µM). Linearity of metabolite formation to ODT and NDT in relation to 
time and protein content was investigated at 0.5 µM tramadol, and seemed to be linear up to 10 min 
and up to 1 mg of microsomal protein per ml.  
Considering only linear kinetic data (initial velocities), the CLapp was calculated, as described in the 
previous section. The intrinsic clearance (CLint) is the apparent in vitro clearance that is maximal and 
constant at the lower end of the substrate concentration test range (illustrated for ODT and NDT in 
figure 2). Estimated enzyme kinetic parameters Km, Vmax, CLint are presented in table 2 with their 
95% confidence intervals.  
Figure 2a+b here 
Table 1 here 
Table 2 here 
 
4.1.2 HLM inhibition assays 
Tramadol metabolism to ODT (figure 3, table 1) was found to be primarily inhibited (80%) by 1 µM 
quinidine, which causes a selective inhibition of CYP2D6 (30). Inhibition of another major CYP 
enzyme, CYP3A and CYP3A4 by ketoconazole and SR-9186 (31), respectively was derived to be 
approximately 15%. The rest of the ODT formation (5%) seemed to be mediated by CYP2B6 as 
indicated by the thioTEPA inhibitory effect. 
Tramadol N-demethylation, displayed in figure 3 and table 1, is mainly mediated by CYP3A4 because 
about 60% of the metabolism to NDT is blocked by chemical inhibition with ketoconazole (1 µM) and 
SR-9186 (2.5 µM). The inhibitory effect of thioTEPA (10 µM) is believed to result from a dual effect on 
CYP3A4 and CYP2B6. This cross-reactivity was investigated by co-incubating tramadol with the 2 
inhibitors. Knowing that SR-9186 causes selective inhibition of CYP3A4, the real contribution of 
CYP2B6 in the NDT formation can be estimated at 30% by subtracting the inhibition of SR-9186 alone 
from the inhibition with SR-9186 + thioTEPA, thereby correcting for thioTEPA’s inhibitory effect on 
CYP3A4.  
Figure 3a+b here 
 
4.1.3 CLint from rCYP assays 
The kinetics of 1 µM to 250 µM tramadol to metabolites ODT and NDT was determined in 
recombinantly expressed enzyme systems containing CYP3A4, CYP2D6, CYP2B6, and insect controls 
(Supersomes™). Linear conditions were determined for both metabolites in relation to time per 
recombinant isoform at 100 pmol/ml. Enzymatic rates were linear up to 5 or 7 min, depending on the 
isoform under investigation. Only linear data should be used for calculation of the CLapp, yielding a 
plateau of CLint at tramadol concentrations well below Km (figure 4). CLint values that were used as 
input for hepatic clearance model 2, the rCYP model, can be found in table 1. 
Figure 4 here  
4.1.4 Blood distribution 
The blood distribution of tramadol appeared to be concentration independent within the test range 
of 0.1 to 10 µM tramadol and the blood-to-plasma ratio was determined at 1.09 (sd 0.02). 
4.2 Simulation results 
4.2.1 Hepatic clearance investigation and population simulation 
The involvement of the hepatic clearance in the total tramadol clearance was investigated by using 
the input from two distinct IVIVE-linked PBPK clearance models (HLM and rCYP model) and the 
retrograde clearance model as reference model. The results of this analysis are presented in figures 
5, 6, and table 3. Input details for every clearance model are provided in the section Materials and 
Methods- Simulations. 
Figure 5 here 
Table 3 here 
 
The HLM model as well as the rCYP model (models 1 and 2) are predicted within 2 fold of the 
observed geometric mean clearance, and the retrograde model, as a reference model, coincides with 
the geometric mean clearance (figure 5). From table 3 it is apparent that the geometric mean 
clearance is slightly underpredicted in the HLM model but is somewhat overpredicted in the rCYP 
model. The variability in every model seems to be slightly underpredicted when compared to the 
observed variability. The CYP2D6 contribution, as illustrated by the fold increase of the hepatic 
clearance in PM vs EM (table 3), is underpredicted by both the HLM and the rCYP model, compared 
to the retrograde model and the observed data (28). 
The steady-state volume of distribution was mechanistically predicted using the Rodgers and 
Rowland model. Preliminary simulations with the Poulin & Theil distribution model (32) resulted in a 
clear underprediction of the volume of distribution (data not shown). This is in line with previous 
reports on the better performing Rodgers & Rowland model, accounting for membrane interaction of 
ionized basic drugs (25, 33), such as tramadol. 
Figure 6 here 
In figure 6 the 3 plots visualize the output from the simulation results by overlaying the in vivo 
observed clearances and PBPK predicted clearances in a plot per considered model. Circles represent 
data from in vivo studies by Lintz et al. and Quetglas et al. (21-24) with the dashed line being their 
overall geometric mean and the dotted line their 95% prediction interval as calculated by Johnson 
(29). Y-axis represents total clearance for the predictions and observations, while the x-axis 
represents an index for the observations only -sorted per individual (Lintz data (21-23)) or per study 
population (Quetglas data (24))-. The greyed area represents the 95% prediction interval on the total 
clearance of the virtual population with its geometric mean as solid black line. Visually, the 95% 
prediction intervals for the rCYP and the retrograde model are more in line with the observed 
interval than for the HLM model, where an underestimation is present. In addition, figure 7 displays 
the observed and predicted values of Vss. Although some underprediction of the geometric mean Vss 
in this case is apparent, the predicted variability is in line with the observed one as can be concluded 
visually from the 95% prediction intervals. 
Figure 7 here 
 
4.2.2 Sensitivity Analysis 
In order to identify those input parameters that significantly affected the PBPK prediction of total 
clearance (CL) and steady-state volume of distribution (Vss), a generalized linear model (glm) was 
fitted to the PBPK prediction outcomes. In this sensitivity analysis, effects of input parameters logP, 
pKa, fraction unbound in plasma (fu), blood:plasma ratio (BP), and hepatic accumulation (ACC) on 
PBPK predicted CL and Vss were determined. Isolated effects and interaction effects were 
distinguished in order to obtain meaningful parameter estimates (table 4). It is worth noting that CL 
values were calculated as dose/AUC from Simcyp output sheets. This means that the predictions of 
CL in this case (PK profiles mode) are not independent from the prediction of Vss, because we record 
AUCs over the 24h period post dose. In short, if input parameters that have an impact on the 
elimination or distribution of the drug are changed, plasma concentrations change, AUC0-24h changes, 
and hence CL (=D/AUC0-24h). The “(Intercept)” from the glm output displays the predicted total 
clearance (19.31 L/h) and volume of distribution (2.77 L/kg) when all five input parameters are at 
their lower level. Increasing the logP, fu, BP and ACC to their higher level, increases the predicted 
total clearance, while increasing pKa has a small but significantly lowering effect on the total 
clearance. An increase in logP and BP increases the predicted Vss, while increasing pKa and fu 
decreases the prediction of Vss. A simultaneous increase in both fu and ACC results in a higher 
predicted CL than what is to be expected from their isolated effects. 
Table 4 here 
It can be concluded from the results in table 4 that based on the values for these 5 input parameters 
encountered in the literature or derived from own experimental work, the B:P ratio (BP) and the 
hepatic accumulation factor (ACC) influenced the prediction of the total clearance most, while mainly 
the B:P ratio (BP) and the unbound fraction in plasma (fu) seemed to be affecting the value of Vss.
 5 Discussion 
In this paper, we investigated the contribution of the hepatic clearance and the different CYP450 
isoforms in the total clearance of tramadol by considering 3 different clearance models. Model 1 
(HLM model) is based on data from HLM systems with specific CYP450 contributions via a chemical 
inhibition assay, while model 2 (rCYP model) uses recombinant in vitro clearance data with ad hoc 
determined ISEF values. Finally, model 3 (retrograde model) was included as a reference model, 
based on hepatic intrinsic clearances scaled back from in vivo hepatic clearance. For every model 
prediction not only the geometric mean of the total clearance but also the associated variability was 
evaluated. The difference in total clearance between these models is solely due to their hepatic 
component since renal clearance was fixed at 6.6 L/h. Apparently, the HLM model underpredicted 
the total clearance by -27%, while the rCYP model overpredicted the total clearance by +22% due to 
the fact that the hepatic clearance is increased in the rCYP model vs the HLM model (cfr figure 6 and 
table 3). The involvement of CYP2D6 still is underestimated in the HLM model and rCYP model, as can 
be concluded from the lower values for hepatic fold increase in table 3 compared to the retrograde 
model. Although a large pool of human liver microsomes was used for the experiments, it has been 
previously shown that CYP2D6 is not the most stable isoform as could be derived from in vitro 
metabolism studies (34), and hence an underestimation of CYP2D6 activity as measured in this HLM 
batch could be a plausible explanation. Despite the fact that the rCYP model, based on study-specific 
ISEFs, somewhat overpredicts hepatic involvement, the CYP2D6 contribution is quite analogous to 
the one in the HLM model. Although an underprediction of -27% (HLM model) and an overprediction 
of +22% (rCYP model) of the total clearance is apparent, the question can be raised how much more 
accurate these bottom-up clearance models need to be. Are we only and unconditionally satisfied 
when the model predictions fall within the 2 fold prediction error margins? In our opinion, although 
our clearance model predictions clearly fall within these boundaries, there is undoubtedly room for 
improvement since a suboptimal CYP2D6 involvement in our clearance models prevails. Additional 
research should enable us to fine-tune these models further in their relative CYP contributions. 
In the evaluation of the population simulations we found that the variability in all three models tends 
to be underpredicted, as is readily observed from the CV fold values being smaller than 1 in table 3. 
Upon visual inspection of figure 6 the variability of the rCYP model predictions seems larger than that 
of the HLM model predictions. However, when comparing the fold differences of CV between the 
two models, it is noticed that the difference between the fold differences (0.73 vs 0.89, table 3) is 
smaller than what would have been expected based on comparison of the 95% prediction intervals 
from the plots in figure 6. This indicates that variability, incorporated in the PBPK predictions, 
assumes a constant CV model. Having a good prior estimate of the variability associated with the 
clearance through the use of PBPK modeling and simulation would definitely facilitate the 
prospective design and power calculations of an upcoming clinical trial. 
In establishing in vitro intrinsic clearance values, using whatever in vitro system, it is well known that 
data should be linear with respect to time and protein concentration (35). Drug-specific HLM and 
recombinant enzyme kinetic data on tramadol are available in the literature (2). The data, however, 
are based on experiments using pools from 5 livers in which linearity was not investigated at the 
lowest in vitro test concentration. Moreover, the experiments were conducted at concentrations 
beyond those ever reached in vivo (intrahepatically). We therefore redesigned these experiments, in 
order to obtain physiologically relevant in vitro enzyme kinetic parameters. From the literature it was 
anticipated that tramadol would have a very low turnover in vitro (36), and our data equally 
substantiated that after 10 min incubation with 1 mg microsomal protein/ml, only 1% of tramadol at 
[S] < Km/10 was converted to its respective metabolites. By using appropriate, physiologically 
relevant incubation conditions, we were able to achieve quantitative estimates for the intrinsic 
clearances for both metabolites. Additionally, next to CYP2D6 and CYP3A4, a role for CYP2B6 of 
about 30% in the HLM metabolism of tramadol to NDT could be identified. This contribution however 
may be overemphasized due to the lower CYP2D6 activity present in this HLM batch. Nevertheless, in 
the case of CYP2D6 poor metabolizers e.g., the contribution of CYP2B6 and its expected associated 
variability (37) may become important covariates in the tramadol disposition. 
An appealing feature of IVIVE-linked PBPK modeling and simulation is the learning-confirming 
principle, and consequently, the fact that mechanistic insights into the observed pharmacokinetics 
can be obtained (38). In that respect, the sensitivity analysis conducted in this case study clearly 
revealed that the B:P ratio and hepatic accumulation were factors most influential for the prediction 
of clearance, while the B:P ratio and fraction unbound in plasma strongly influenced the prediction of 
steady-state volume of distribution. While it is obvious why e.g. the hepatic accumulation and 
unbound fraction in plasma determine the prediction of the clearance and volume, respectively, it is 
not directly evident why the B:P ratio has such a marked effect, while logP and pKa hardly have any 
effect on the prediction of the tramadol clearance (table 4). It has to be kept in mind however, that 
all predictions are based on kinetics as a function of time after a single iv dose, recording plasma 
concentrations up to 24h post dose. Because B:P ratio, logP, and pKa all influence the prediction of 
the volume of distribution, and hence plasma concentrations, this has a rebound effect on the 
calculation of the clearance, calculated as dose/AUC0-24h. The influence of the B:P ratio on the Vss 
was anticipated considering its role in the Rodgers & Rowland model for the prediction of tissue 
distribution (25). Therefore, a blood distribution experiment was conducted to ascertain the value of 
this B:P ratio in the model. Also, the positive effect of hepatic accumulation on the prediction of the 
hepatic clearance value proved to be a very influential factor in this PBPK model, which is to be 
expected for low clearance drugs. Tramadol, as basic amine, is expected to accumulate inside the 
hepatocyte, solely driven by the existing pH gradient from 7.4 outside the cell, over 7.2 in the cytosol, 
to 5 in lysosomes (39). No transporters are thought to be involved in this process (6), which is in line 
with tramadol’s BCS class I. An important issue in this matter is to establish which fraction of drug is 
available to the CYP450 enzyme system. The CLint, as determined in vitro in hepatocyte suspensions, 
should provide an indirect measure of the accumulation of unbound drug inside the hepatocyte, that 
is readily available for biotransformation. Nevertheless, a substantial underestimation of the CLint 
using hepatocyte incubations is a recognized problem (40, 41) and questions concerning the 
presence of a comparable pH gradient in such an in vitro setup have arisen (42, 43). Additionally, 
Poulin and co-workers also stated that the unbound drug fraction inside the hepatocyte could be 
greater than the unbound fraction in plasma because of binding effects of albumin on the hepatocyte 
cell surface in vivo on the one hand, and the aforementioned pH difference for ionizable compounds 
on the other hand. Consequently, by using in vitro systems in which these effects are unaccounted 
for, the CLint could be underestimated (44). Because of the inability to determine this uptake, a 
hepatic accumulation value of 1.58 (39) was used in all clearance models, based on the pH difference 
between the hepatocyte’s outer (7.4) and inner (7.2) environment. To be able to put this into 
context, quite recently, equations were published by Berezhkovskiy et al. (42) that can be used to 
calculate an ionization factor, describing a drug’s trapping behavior based on the drug’s pKa and the 
pH difference over the hepatocyte membrane. These equations revealed that for tramadol by varying 
the intracellular pH between 7.0 and 7.2, the ionization factor takes on values of 1.67 and 2.5, 
respectively. In analogy, varying the hepatic accumulation factor 2-fold (from 1.5 to 3) in our 
sensitivity analysis increased prediction of the clearance with 33%. This indicates that small changes 
in pH can introduce significant changes in tissue-to-plasma concentration ratios. A better 
characterization of the relevant processes at hand could improve clearance prediction accuracy from 
an IVIVE perspective.  
 
6 Conclusion 
In conclusion, based on this work, we document that for quantitative PBPK modeling & simulation, all 
experiments to determine enzyme kinetic parameters should be performed with concentrations 
mimicking the in vivo obtained concentrations as closely as possible, while at the same time carefully 
scrutinizing reaction linearity. Tramadol as such displays a low turnover in hepatic in vitro systems, 
but using the physiological integration features of IVIVE-PBPK, i.e. the combination with a high 
fraction unbound in plasma (80%) and the hepatic accumulation (1.58 fold) of tramadol, leads to a 
simulation result corresponding with the quite extensive metabolism (approximately 80% of dose) 
observed in vivo. Three distinct clearance models were described in this paper. The HLM model 
slightly underpredicted, while the rCYP model slightly overpredicted the geometric mean clearance. 
The CYP2D6 contribution was underpredicted in both cases. Although the variability also suffered 
from some underpredicition, the predicted coefficients of variation were in line with observed ones. 
We clearly illustrated that the use of a retrograde model as reference model facilitates the bottom-
up PBPK model building process. The IVIVE-linked PBPK approach has proven to be a very useful tool 
in integrating available in vitro, in silico, and in vivo data on tramadol to successfully predict the in 
vivo PK and gain mechanistic insight in relevant disposition covariates at hand. 
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 Figures 
Figure 1: Tramadol CYP450 metabolism pathways (O-desmethyltramadol (ODT); N-desmethyltramadol (NDT); NODT 
(N,O-didesmethyltramadol)) 
 
 
Figure 2: the observed in vitro clearance (µL/min/mg microsomal protein) in relation to the incubation concentrations 
(µM) of tramadol for ODT (A) and NDT (B). For ODT the plateau of intrinsic clearance (CLint) is reached at 0.80 µl/min/mg 
protein, and for NDT the CLint was estimated at 1.63 µl/min/mg protein. 
 
 
Figure 3: The inhibition plot represents rest fractions of metabolite ODT (A) and NDT (B) in relation to inhibitor(s) 
present. A linear control was always run in parallel to the inhibition assays to determine 100% ODT and NDT formation. 
 Figure 4: the apparent in vitro clearance (µL/min/pmol CYP) for ODT and NDT in relation to the incubation 
concentrations (µM) of tramadol, for every recombinant enzyme CYP3A4, 2D6 and 2B6. 
 
Figure 5: the prediction of the total clearance per clearance model. Black dots are predicted geometric mean clearance 
and error bars represent the standard deviations. Dashed and dotted lines represent the observed geometric mean and 
their 2 fold boundaries, respectively. HLM model: hepatic clearance model from human liver microsomes; rCYP model: 
hepatic clearance model from recombinant human enzymes; Retrograde model: hepatic clearance model from in vivo 
observed clearance data 
 
Figure 6: population simulation results for total clearance by the 3 models considered in this paper. Open circles (Lintz 
data (20-22)) and black circle (mean +- 2*sd) (Quetglas data (23)) represent data from in vivo studies with the dashed line 
being their overall geometric mean and the dotted line their 95% prediction interval. The greyed area represents the 95% 
prediction interval of the simulated population with its geometric mean as solid black line 
 
 
Figure 7: population simulation results for volume of distribution (Vss). Since we only considered 1 distribution model, 
only 1 plot is presented. Open circles (Lintz data (20-22)) and black circle (mean +- 2*sd) (Quetglas data (23)) represent 
data from in vivo studies with the dashed line being their overall geometric mean and the dotted line their 95% 
prediction interval. The greyed area represents the 95%prediction interval of the simulated population with its geometric 
mean as solid black line. 
 
 
 
 
 
 
 
Tables 
Table 1: overall summary of the CLint values obtained in kinetic experiments that were used as input for PBPK. 
Specific CYP isoform contribution is incorporated through chemical inhibition (model 1) or ISEF values (model 2) or 
back-calculated from in vivo (model 3) for ODT and NDT. 
Model Formula CYP isoform CLint ODTa  CLint NDTa  
1 HLM b 
 
CLintHLM 
(CLintODT/NDT * %CYP by chemical inhibition data) 
3A4 0.12 
(0.80*15%) 
1.06 
(1.63*65%) 
2D6 0.64 
(0.80*80%) 
0.08 
(1.63*5%) 
2B6 0.04 
(0.80*5%) 
0.5 
(1.63*30%) 
2 rCYP c 
 
CLintrCYP * ISEF 3A4 0.00   *0.23 0.11   *0.23 
2D6 0.57   *0.45 0.054 *0.45 
2B6  0.018 *0.43 0.20   *0.43 
3 RGd Retrograde model 2D6 48% of HepCL 
3A4+2B6 52% of HepCL 
a CLint values for model 1 are expressed as µl/min/mg protein, whereas for model 2 CLint is 
expressed as µl/min/pmol CYP450 
b reported CLint values are obtained by multiplication of the CLintHLM values with % CYP isoform 
contribution calculated  from inhibition assay data 
c CLintrCYP obtained from recombinant enzyme systems, are presented with their specific ISEFs 
d Retrograde model allows the user to set specific CYP contributions based on in vivo data in CYP2D6 
PM and EM 
Table 2: overview of enzyme kinetic parameters Km, Vmax and CLint and their associated 95% confidence intervals for 
tramadol’s two main metabolites ODT and NDT in pooled HLM 
 ODT NDT 
Km [95% CI] 
(µM) 
57.5 [47.0 ; 71.1] 242 [174 ; 353] 
Vmax [95% CI] 
(pmol/min/mg protein) 
46.4 [38.9 ; 56.1] 395 [290 ; 565] 
CLint [95% CI] 
(µl/min/mg protein) 
0.80 [0.78 ; 0.84] 1.63 [1.57 ; 1.69] 
 
 Table 3: Hepatic clearance investigation by comparison of 3 PBPK models. 
First, the 3 models are presented with their renal, hepatic and 2D6 involvement, relative to the total clearance. 
Second, the 3 models are compared by their relative difference in geometric mean and fold of coefficients of variation 
(CV) versus observed data. Furthermore, the increase in hepatic clearance between CYP2D6 PM and EM is a measure of 
CYP2D6 contribution, indicating an underinvolvement of CYP2D6 in both the HLM and the rCYP model 
 HLM model 1 rCYP model 2 Retrograde model 3 
Renal involvement (%) 43 24 29 
Hepatic involvement 
(%) 
57 76 71 
2D6 involvement in 
hepatic clearance (%) 
29 29 44 
2D6 involvement in 
total clearance (%) 
17 22 31 
Comparison of geometric mean and coefficient of variation 
Relative difference in 
geometric Mean 
-27% +22% +1% 
Fold difference in CV 0.73 0.89 0.85 
Hepatic clearance fold increase 
HepCL fold increase for 
CYP2D6 PM to EM 
1.39 1.33 1.73a 
 a observed hepatic clearance increase was calculated at 1.74 (27)
 Table 4: Sensitivity analysis by a generalized linear model (glm). 
The isolated and interaction effects of input parameters on the geometric mean total clearance (CL) and volume of 
distribution (Vss) are displayed with significance level. (Intercept) has the value of the CL or Vss when all variables are at 
their lower input level. The estimate for a specific variable represents the increase/decrease in CL or Vss when this 
variable is changed to the higher input level 
 Input 
level 
Coefficients for CL (L/h)
a
 Coefficients for Vss (L/kg)
a
 
 low – high Estimate Significance Estimate Significance 
(Intercept)  19.31 *** 2.77 *** 
logP 1.35 – 
2.41 
+0.19 *** +0.070 *** 
pKa 9.13 – 
9.44 
-0.020 ** -0.0075 *** 
fu 0.74 – 
0.80 
+0.025 ** -0.23 *** 
BP 1.09 – 
1.20 
+2.84 *** +1.12 *** 
ACC 1.5 – 3 +6.32 *** - -
 
 
logP:pKa9.44  -0.098 *** -0.040 *** 
logP:fu0.8  -
 
 -
 
 +0.010 *** 
fu:BP1.2  -0.13 *** -
 
 -
 
 
fu:ACC3  +0.49 *** -
 
 -
 
 
BP:ACC3  -0.17 *** -
 
 -
 
 
pKa:fu0.8  -
 
 -
 
 -0.0050 ** 
pKa:BP1.2  -
 
 -
 
 -0.0050 ** 
a 
Signif. codes  ‘***’ 0 ; ‘**’ 0.001 ;  ‘-’ coefficient for this variable did not contribute significantly to the model 
 
 
